Contemporary Pediatrics connects pediatricians with peer-reviewed articles, guideline updates, and practice strategies for real-world clinical application.

Joshua Fitch is the senior editor for Contemporary Pediatrics. He joined the brand in March of 2023 as an editor before being promoted to senior editor in January 2024. Fitch graduated from Youngstown ...

A session of the American College of Obstetricians and Gynecologists 2021 annual meeting pointed to the dramatic increase in sexually transmitted infections (STIs) in the United States and presented ...

As RSV prevention tools expanded, clinicians faced new decisions around allocation, coordination, and outreach. In the final installment of this 3-part HCP Live Network RX Review roundtable, moderator ...

This episode focused on the most pressing unmet needs in RSV prevention and the clinical impact of newly approved options. Tan highlighted a key issue from the initial rollout of nirsevimab: supply ...

Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants and young children, placing a significant burden on families, hospitals, and the healthcare system. Recent ...

The FDA has accepted a new drug application (NDA) for epinephrine sublingual film (Anaphylm; Aquestive Therapeutics) to treat type 1 allergic reactions, including anaphylaxis. With the acceptance of ...

The FDA has approved, for patients aged 12 years and older, CSL's garadacimab-gxii (Andembry) to prevent attacks of hereditary angioedema (HAE), according to a press release from the company. With the ...

The FDA will not meet a prescription drug user fee act (PDUFA) date of June 17, 2025, for a decision regarding the potential approval of sebetralstat (KalVista Pharmaceuticals) to treat hereditary ...

On June 15, 2025, the FDA announced the approval of a new presentation of ustekinumab-stba (Steqeyma; Celltrion), a biosimilar to ustekinumab (Stelara; Janssen Biotech), in a 45mg / 0.5mL solution in ...

Fathers’ diets during their teenage years may play a lasting role in shaping the nutritional behaviors of their children, according to findings presented at the American Society for Nutrition’s annual ...

On June 12, a new phase 3 clinical study of the Vimkunya single-dose, virus-like particle (VLP) chikungunya vaccine was initiated by Bavarian Nordic A/S among children aged 2 to 11 years, according to ...